Dr RR Baliga's "Got Knowledge Doc" Podkast

🚨 New insights from the Lancet ! 🚑 In the OPTION–STEMI trial, immediate multivessel PCI during the index procedure failed to show non-inferiority compared to staged revascularisation in STEMI patients with multivessel disease.   🧠 Key takeaway? Timing matters. ⚠️ Higher risk in those with heart failure (Killip II/III) 💡 Safer strategy: staged PCI for high-risk patients   📊 Fractional flow res...

✨ St. Thomas Aquinas (1225–1274) — Dominican friar, philosopher & theologian — is among the most influential thinkers in Western tradition. 📖 His Summa Theologica shaped Catholic theology, blending Aristotle's philosophy with Christian faith. 🕊️ Known as the Doctor Angelicus , he championed faith & reason, natural law ⚖️, and virtue ethics 💡— principles that still guide philosophy, theology, an...

🚨 New Podcast Drop! 🎙️ "VICTOR, Vericiguat, and Victory?" unpacks the Lancet trilogy — the VICTOR trial, pooled analysis, and expert commentary 🧠📊💊. We explore Vericiguat's evolving role across the heart failure spectrum 💓📉 and what it means for clinical care in HFrEF patients.   📚 Trials discussed: VICTOR, VICTORIA 🎧 Tune in for insights on risk-based treatment effects, NT-proBNP threshol...

🎭 Just explored a landmark Nature Medicine review on how the arts can prevent noncommunicable diseases (NCDs) across 27 countries! 🎨 From dance and drama to gardening and storytelling, arts-based interventions improved physical activity, diet, and mental well-being—especially in underserved communities. 📊 A must-read for anyone interested in health equity , cultural relevance , and community-le...

💊 Orforglipron : A new era in obesity treatment?   In the ATTAIN-1 trial, this oral, nonpeptide GLP-1 receptor agonist delivered up to 11.2% weight loss over 72 weeks—with significant drops in waist circumference, triglycerides, and blood pressure 📉🌡️   🔥 Nearly 1 in 5 patients lost ≥20% body weight 💡 A promising alternative to injectable therapies   Accessible. Effective. Oral. 👉 A game-chan...

🚨 New Podcast Drop! 🎙️ "Myosin, Metrics & Momentum 🧬📈🫀" dives into 3 landmark NEJM articles on Aficamten vs Mavacamten in hypertrophic cardiomyopathy.   We decode: 🔹 MAPLE-HCM (obstructive HCM) 🔹 ODYSSEY-HCM (nonobstructive HCM) 🔹 Expert editorial insights on PROs, EF, & trial design   🎯 Learn what matters: peak VO₂ vs PROs, safety signals, and the road ahead in precision cardiomyopathy ca...

  💊 New Hope in a Pill for Obesity? The 71-week OASIS 4 trial shows that oral semaglutide 25 mg led to a 13.6% weight loss , improved physical function, and reversed prediabetes in 71% of cases—all without injections. 📉 Effective. 🧬 Metabolically beneficial. 📦 Orally delivered.   #ObesityCare #GLP1 #Semaglutide #NEJM #DigitalHealth #Cardiometabolic

☀️ Walking on Sunshine? Rethinking Our Relationship with the Sun! 🧴🧬 New research—spotlighted in The Economist (Sep 20, 2025)—challenges old assumptions: Could moderate sun exposure reduce cardiovascular mortality? ❤️📉 From nitric oxide to vitamin D, this FAQ explores the science, nuance, and shifting global guidelines. Let's talk melanin, mortality, and medicine! 🌍💡 #Sunlight #Cardiovascular...

🚨 Cardiogenic Shock—A Decade Later The DanGer Shock Trial shows that patients with STEMI and shock treated with the Impella CP microaxial flow pump lived 600 more days over 10 years vs standard care alone. 📉 Mortality: 52.5% vs 68.8% (HR 0.70) 🛠️ Despite higher adverse events, the survival benefit endured a full decade . 📊 This changes how we think about long-term outcomes in mechanical support...

🧠 Hypertrophic Cardiomyopathy — A Masterclass from Eugene Braunwald 🧬   📌 Just published in NEJM (Aug 2025): a sweeping, state-of-the-art review on HCM — from Teare's first autopsy to myosin inhibitors , AI diagnostics , and gene therapy .   💥 Clinical insights, historical depth, trial data (EXPLORER-HCM, SEQUOIA-HCM, VALOR-HCM), and future-facing advances—all distilled into one must-read.  ...

🚨 New NEJM Study on Olezarsen 🚨 In patients with moderate hypertriglyceridemia and elevated cardiovascular risk , monthly subcutaneous olezarsen reduced triglycerides by over 60% at 6 months! 📉💥   ✅ Significant drops in APOC3, VLDL, remnant & non-HDL cholesterol ✅ No rise in LDL-C ✅ Well-tolerated with mild injection-site reactions   🔬 APOC3 inhibition emerges as a game-changer in lipidolo...

🌸 Dōgen Zenji (1200–1253), founder of the Sōtō Zen school in Japan, taught that true practice lies in zazen—"just sitting" 🧘‍♂️ —where enlightenment and practice are inseparable. His  Shōbōgenzō continues to inspire mindfulness & presence today. ⏳✨ #Zen #Mindfulness

🚨 New Evidence in NSTEMI Care! 🫀 The SLIM Trial shows that FFR-guided complete revascularization during the index procedure in patients with NSTEMI and multivessel disease significantly reduces death, MI, stroke, and repeat PCI compared to culprit-only PCI.   🎯 Key win? Fewer revascularizations, better outcomes — physiology beats anatomy again.   📚 Published in JAMA , presented at #ESC2025 🔗...

💥 Practice-Changing Evidence in HFpEF! 💥 In a real-world cohort of 97,000+ patients with obesity & type 2 diabetes, semaglutide and tirzepatide reduced risk of heart failure hospitalization or death by over 40% 📉 ⚖️ No meaningful difference between the two agents. 🧠 Findings reinforce STEP-HFpEF & SUMMIT trials and highlight GLP-1 therapies' expanding role in cardiometabolic HFpEF 🫀 #Cardiolo...

📢 Just read the #AMALFI trial in JAMA 📰 — a landmark remote RCT of AF screening using 14-day ECG patches mailed to older adults at stroke risk 📦🫀. At 2.5 years, the patch group had a modestly higher AF detection rate (6.8% vs 5.4%, p=0.03) and increased anticoagulation use 💊🧠. Stroke rates were similar ⚖️.   🎯 Key takeaway: Remote, mail-based AF screening is feasible and nudges diagnosis ra...

🚨 New Trial Alert 🚨 Can we safely stop anticoagulation after AF ablation? The ALONE-AF Trial 🫀 suggests yes —in selected patients with no AF recurrence, stopping DOACs reduced major bleeding 🌟 without increasing stroke risk 🧠.   📉 0.3% vs 2.2% for the composite outcome (P = .02) 📍 Carefully monitored, low-risk patients may benefit most.   📝 Editorial: Recommends shared decision-making 🤝 &...

🚨 New Findings from the HELP-MI Trial! 🇸🇪🧪 Can routine Helicobacter pylori screening during acute myocardial infarction (MI) hospitalization prevent upper gastrointestinal bleeding (UGIB)?   💉 Over 18,000 patients across 35 Swedish hospitals 📉 Result: No significant reduction in UGIB overall (RR 0.90; P=0.18) 🔍 BUT: Clear benefit in patients with anemia (RR 0.44–0.64) and chronic kidney disea...

🩺 New Insights on Apixaban for VTE! 📢 The HI-PRO trial challenges the old 3-month rule for provoked VTE. 📉 Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE from 10.0% ➡️ 1.3% with minimal major bleeding. 🎯 Editorial in NEJM urges a shift from binary labels ("provoked vs unprovoked") to a patient-centered, risk-adapted approach. 🧠 Art meets evidence in the decision to extend antic...

🌏 Zhu Xi (1130–1200), a master of Neo-Confucianism , reshaped Chinese philosophy with his focus on rationality, self-cultivation & education . His commentaries on the Four Books guided civil service exams for centuries across East Asia. 📚✨   #Leadership #Philosophy #History #Confucianism

Just read the latest from NEJM? The PIpELINe Trial 🇮🇹 changes how we approach cardiac rehab in older adults post-MI! 🧓❤️ 🎯 A 12-month, multidomain intervention — risk factor control, nutrition 🥗, and Otago-based exercise 👟 — cut CV death/hospitalization from 20.6% → 12.6% (P=0.01)! 📉 Hospitalizations for heart failure dropped 7.1% → 1.5% . No serious adverse events. And yes — better gait spee...

🚨 New Meta-Analysis Alert! 💊🫀 Can β-blockers benefit patients post-MI with mildly reduced ejection fraction (LVEF 40–49%)?   📊 An individual patient data meta-analysis (REBOOT, BETAMI, DANBLOCK, CAPITAL-RCT) shows a 25% reduction in the composite outcome of death, MI, or HF with β-blockers vs. control (HR 0.75; p =0.031) — even in the absence of clinical heart failure.   🌍 Consistent across t...

🚫💊 Should We Rethink Beta-Blockers Post-MI? In the landmark REBOOT trial (NEJM, 2025), beta-blockers failed to reduce mortality, reinfarction, or heart failure hospitalizations in post-MI patients with preserved ejection fraction (>40%).   💡 A modern, pragmatic trial across 109 centers (Spain + Italy 🇪🇸🇮🇹) with 8438 patients — shaking the foundation of our long-held post-MI practices. 👩‍⚕️ Sig...

🚨 New NEJM Study Alert! 🩺💔 Do beta-blockers still help after a heart attack if there's no heart failure? 🤔   In the BETAMI–DANBLOCK trial (🇩🇰+🇳🇴, n=5574), beta-blocker therapy in post-MI patients with preserved or mildly reduced LVEF (≥40%) modestly reduced the composite outcome of death or major cardiovascular events 🧠📉   📌 Primary endpoint: 14.2% (BB) vs. 16.3% (no BB) → HR 0.85, p =0.03...

💥 New NEJM Trial Alert! A modest 0.3 mmol/L rise in potassium (via MRA, KCl, or diet) significantly reduced arrhythmias, ICD shocks, and hospitalizations in high-risk ICD patients ⚡🫀   📉 HR 0.76 for the composite endpoint 🔢 NNT = 12.3 over 3.3 years 🍌 Safe, scalable, and globally relevant   👉 Time to rethink "normal" K⁺ levels in cardiology! #Cardiology #Electrophysiology #NEJM #ICD #Potass...

🚨 New RCT Alert from the NEJM ! Can an old 💊 make a comeback in modern 💓 failure care?   📌 The DIGIT-HF trial showed that digitoxin , a cardiac glycoside with hepatic clearance, reduced the combined endpoint of all-cause death or HF hospitalization in HFrEF patients on contemporary guideline-directed therapy — including ARNI, beta-blockers, MRAs & SGLT2i. 🩺 HR = 0.82; p = 0.03 📉 👩‍⚕️ Safe i...